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Objective: The present study was designed to evaluate the molecular epidemiology of CTX-M
producing  Klebsiella pneumoniae, Enterobacter cloacae and Escherichia coli isolated from blood-
stream  infections at tertiary care hospitals in the State of Rio de Janeiro, Brazil.
Material and methods: A total of 231 nonduplicate Enterobacteriaceae were  isolated from
ﬁve  Brazilian hospitals between September 2007 and September 2008. The antimicrobial
susceptibility  testing was performed by disk diffusion method according to the Clinical Lab-
oratory Standard Institute. Isolates showing resistance to third-generation cephalosporins
were  screened for ESBL activity by the double-disk synergy test. The presence of blaCTX-M,
blaCTX-M-15 and blaKPC genes was determined by Polymerase Chain Reaction (PCR) ampliﬁca-
tion  and DNA sequencing. The molecular typing of CTX-M producing isolates was performed
by  pulsed-ﬁeld gel electrophoresis (PFGE).
Results and discussion: Ninety-three isolates were screened as ESBL positive and 85 (91%)
were  found to carry CTX-M-type, as follows: K. pneumoniae 59 (49%), E. cloacae 15 (42%), andE.  coli 11 (15%). Ten isolates resistant for carbapenems in K. pneumoniae were blaKPC-2 gene
positive.  Among CTX-M type isolates, CTX-M-15 was  predominant in more  than 50% of
oniae, E. coli, and E. cloacae. PFGE analysis of CTX-M producing isolatesisolates for K. pneumshowed  the predominance of CTX-M-15 in 10 of 24 pulsotypes in K. pneumoniae, 6 of 13 in E.
cloacae and 3 of 6 in E. coli. CTX-M-15 was also predominant among KPC producing isolates.
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In conclusion, this study showed that CTX-M-15 was circulating in Rio de Janeiro state in
2007–2008. This data reinforce the need for continuing surveillance because this scenario
may have changed over the years.
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13 Entroduction
ince the end of the 1990s, the CTX-M enzymes have
pread among the continents, becoming the most prevalent
n  the world.1 Among CTX-M-type, speciﬁcally CTX-M-15 is
he  most widely distributed in Escherichia coli and Klebsiella
neumoniae.2–4 Particularly, several reports have shown that
TX-M-15-producing E. coli isolates are closely associated
ith  a single clone disseminated worldwide, which is repre-
ented  as sequence type (ST) 131 and serotype O25:H4.4,5 In
.  pneumoniae, CTX-M-15 had been found in many  countries
ssociated with quinolone resistant strains that belonged to
T11.2,3,6
In South American countries (including Brazil), isolates
arboring the CTX-M-2 have been the most frequent CTX-
-type  detected.7–9 The occurrence of blaCTX-M-15 was  ﬁrst
eported in clinical isolates of E. coli and K. pneumoniae in
he  state of São Paulo.10,11 In the Rio de Janeiro state, the
laCTX-M-15 was  found in E. coli isolates associated with a dom-
nant  clone (sequence type 410).12
Despite many  reports of CTX-M producing isolates in
razilian hospitals, few studies have been conducted about
he  molecular epidemiology of CTX-M-producing Enterobacte-
iaceae  isolates. Thus, the main objective of this study was  to
valuate the molecular epidemiology of CTX-M-producing K.
neumoniae,  E. coli, and E. cloacae, using molecular typing by
ulsed-ﬁeld  gel electrophoresis (PFGE) in bloodstream isolates
ollected  in the period of 2007–2008 from patients admitted to
ve hospitals located in the state of Rio de Janeiro, Brazil.
aterial  and  methods
acterial  isolates
s part of the Bacterial Nosocomial Infection Resistance
urveillance Network, a total of 231 consecutive non-duplicate
.  pneumoniae, E. coli, and E. cloacae isolates originated from
loodstream infections were  collected from inpatients dur-
ng  the period from September 2007 to September 2008, in
ve  public tertiary care hospitals located in the state of Rio
e  Janeiro, Brazil. All species were conﬁrmed by using both
onventional techniques and the automated Vitek System
BioMérieux, Marcy,  I’Etoile, France).
ntimicrobial  susceptibility  testing  and  conﬁrmation  of
SBL production
he isolates were  tested for antimicrobial susceptibility
© 20sing the disk diffusion method according to the Clini-
al  and Laboratory Standards Institute (CLSI) guidelines.13
he following antibiotic disks (Oxoid, Basingstoke, Hants,
ngland)  were  used: ceftazidime (CAZ), cefotaxime (CTX),cefepime  (FEP), aztreonam (ATM), ciproﬂoxacin (CIP), gen-
tamicin  (CN), amikacin (AK), trimethoprim/sulfamethoxazole
(SXT), ertapenem (ETP), meropenem (MEM), and imipenem
(IPM).  Results were  interpreted according to the guidelines
of  the CLSI.14 Isolates showing resistance to third-generation
cephalosporins were  screened for ESBL activity by the double-
disk  synergy test (DDST) using Oxoid disks.15
PCR  ampliﬁcation  and  DNA  sequencing
In isolates screened as ESBL producers, we  performed Poly-
merase  Chain Reaction (PCR) ampliﬁcation to determine the
presence  of blaCTX-M using primers and conditions previ-
ously described.16 In isolates considered positive, another
PCR  for blaCTX-M-15 was performed.16,17 In isolates show-
ing resistance to carbapenems, we performed the PCR
methodology for blaKPC gene detection. The PCR prod-
ucts were puriﬁed using the GFXTM PCR DNA and Gel
Band Puriﬁcation Kit (GE Healthcare, Buckinghamshire, UK)
and  sequenced.18 Sequence analysis and alignment results
were  compared with sequences available from GenBank
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Pulsed-ﬁeld  gel  electrophoresis
Genomic DNA analysis of K. pneumoniae, E. coli, and E. cloa-
cae  isolates were  performed by PFGE, after digestion with XbaI
(Roche  Diagnostics, Indianapolis, IN, USA), using the Chef-DR
III  System (Bio-Rad Laboratories, Richmond, CA, USA). DNA
relatedness  was  computationally analyzed using BioNumerics
v.4.0  software (Applied Maths, Sint-Martens-Latem, Belgium).
The  banding patterns were compared by using the unweighted
pair-group method with arithmetic averages (UPGMA), with
the  Dice similarity coefﬁcient required to be >80% for the
pattern  to be considered as belonging to the same PFGE
type.
Results
Of the 231 bloodstream isolates of Enterobacteriaceae from
patients  admitted to general medical wards or intensive care
units,  93 isolates were  screened as positive for ESBL by phe-
notypic  test. Among ESBL producers, 85 isolates were  found
to  carry CTX-M-type determinants (91%). The distribution of
CTX-M  among the species was: 59 of 121 isolates for K. pneu-
moniae  (49%), 15 of 36 for E. cloacae (42%), and 11 of 74 for
E.  coli (15%). The CTX-M-15-positive isolates represented 61%
of  CTX-M-producers distributed among the species as follows:
64%  (38/59) for K. pneumoniae, 53% (8/15) for E. cloacae, and 55%
lsevier Editora Ltda.Este é um artigo Open Access sob a licença de CC BY-NC-ND(6/11)  for E. coli (Table 1).
The antimicrobial susceptibility testing for CTX-M-
producing Enterobacteriaceae isolates showed that all isolates
were  resistant to cefotaxime (100%), while 76%, 71%, and
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Table 1 – Characteristics of the CTX-M-producing Enterobacteriaceae isolates.
Species Antimicrobial resistance, n (%) -Lactamases genes, n (%)
CAZ CTX FEP ATM CN AK CIP SXT IP MER ERT blaCTXM-15 blaKPC
K. pneumoniae 48  59 45 27 26 15 46 51 10 10 10 38 10
(n = 59) (81)  (100) (76) (46) (44) (25) (78) (86) (17) (17) (17) (64) (17)
E. cloacae 10 15 9 6 9 4 8 13 – – 9 8 –
(n = 15) (66) (100) (60) (40) (60) (26) (53) (87) (60) (53)
E. coli 7 11 6 3 3 4 10 9 – – – 6 –
(n = 11) (64) (100) (55) (27) (27) (36) (91) (82) (55)
Total 65 85 60 36 38 23 64 73 10 10 19 52 10
(n = 85) (76) (100) (71) (42) (45) (27) (75) (86) (12) (12) (22) (61) (12)
CAZ, ceftazidme; CTX, cefotaxime; FEP, cefepime; ATM, aztreonam; CN, gentamicin; AK, amikacin; CIP, ciproﬂoxacin; SXT, trimetho-
prim/sulfamethoxazol; IP, imipenem; MER, meropenem; ERT, ertapenem; n, number of isolates; (%), percentage.
Table 2 – Distribution of the pulsotypes of CTX-M-producing K. pneumoniae, E. cloacae and E. coli isolates in ﬁve hospitals
in Rio de Janeiro.
Hospitals Pulsotypes
K. pneumoniae E. cloacae E. coli
H1 A, B, C, E, M, N, Q, S, T, V, X C, J B, C
H2 A, C, D, E, F, H, I, J, L, P, U, Y, Z B, C, E, F, H, J, K, L, M B, C, D
H3 A, B, C, F, H, I, O – A, B, C
H4 B, C, D, J, K 
H5 F, G 
42% were  resistant for ceftazidme, cefepime, and aztre-
onam,  respectively. In addition, co-resistance for amikacin
(27%),  gentamicin (45%), ciproﬂoxacin (75%), and trimetho-
prim/sulfamethoxazole (86%) was  observed. We  found 10
isolates  of K. pneumoniae and nine of E. cloacae showing resis-
tance  to the tested carbapenems. PCR for blaKPC gene showed
that  17% (10/59) of CTX-M-producing K. pneumoniae isolates
were  positive and this gene was  not detected in nine isolates
of  E. cloacae resistant to ertapenem (Table 1). In our isolates of
K.  pneumoniae KPC-2 type were found in four hospitals studied
in  2007 and 2008. Among the KPC isolates, CTX-M-15 was
observed  in 80% of isolates (8/10).
Genetic polymorphism analyses showed 24 different pulso-
types  in K. pneumoniae, designated from A–Z, displaying >80%
similarity  within each type. Of the 59 K. pneumoniae isolates, 30
(51%)  belonged to four dominant pulsotypes: A (n = 7), B (n = 8),
C (n = 9), and D (n = 6). The blaCTX-M-15 was  found in 10 pulso-
types (A, B, C, D, F, J, T, U, Y, and Z). All isolates of pulsotype
A  (n = 7) and one isolate of each pulsotypes D, F, and H were
KPC  producers. The CTX-M-producing K. pneumoniae pulso-
types  were  distributed among the hospitals as showed in Table
2.  Other groups of CTX-M were  also found in K. pneumoniae
(Fig. 1).
Genetic polymorphism analyses of E. cloacae showed 13 pul-
sotypes.  The blaCTX-M-15 was  found in six pulsotypes (C, F, G,
J,  K, and M),  in the hospitals designated H1, H2, and H5. The
group  9 of blaCTX-M gene was  found in seven isolates of E. cloa-
cae  and in seven pulsotypes (A, B, D, E, H, I, and L) (Fig. 2). Of the
four  E. coli pulsotypes (A, B, C, and D) observed, eight isolates
(73%)  belonged to pulsotypes B (four isolates; four hospitals),
and  C (four isolates; three hospitals). The blaCTX-M-15 was  found
in  six isolates, three pulsotypes (A, B, and C) and four hospi-
tals  (H1, H2, H3, and H5). The groups 2 and 8 of blaCTX-M gene– –
A, D, G A, B
also were found in E. coli (Fig. 3). The distribution of pulso-
types  of E. cloacae and E. coli isolates among the hospitals was
demonstrated in Table 2.
Discussion
CTX-M-producing organisms are a clinical problem
worldwide,1 particularly in Latin American countries and
especially  in Brazil, where high endemic rates in Enterobac-
teriaceae isolates have been reported.8,9 In this study, we
observed that the majority of the ESBL-producing isolates
(91%)  were  characterized as CTX-M-producers, supporting
the  recognition of CTX-M as the most prevalent type of ESBL
in  the world.1 K. pneumoniae and E. cloacae were  the most
prevalent CTX-M-producing species.
In this study, CTX-M-producing Enterobacteriaceae
isolates had high rates of resistance to sulfamethox-
azole/trimethoprim, ciproﬂoxacin and gentamicin.
Co-resistance to antimicrobial agents other than beta-
lactams among ESBL and KPC producing isolates has been
very  common, imposing severe restriction on therapeutic
choices for patients with such infections. Resistance to
other  classes of antimicrobial agents may  be due to simulta-
neous  transference of the resistance genes via plasmids and
integrons.19
In this report, we analyzed the molecular epidemiology
of CTX-M in ﬁve hospitals from Rio de Janeiro (Brazil). We
observed  the emergence of CTX-M-15 among bloodstream iso-
lates in 2007–2008.
The  predominance of the blaCTX-M-15 gene involved in dif-
ferent pulsotypes of K. pneumoniae, E. cloacae, and E. coli is
important  because it is representative of the epidemiology at
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Fig. 1 – Clinical data and molecular typing of CTX-M-producing K. pneumoniae.
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CTX-M-9 Group
CTX-M-9 Group
CTX-M-9 Group
CTX-M-15
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CTX-M-15
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 typFig. 2 – Clinical data and molecular
that time. Usually, in K. pneumoniae and E. coli, species, the
CTX-M-15  has been reported as the dominant type of CTX-M in
many countries causing nosocomial and community acquired
infections  by both clonal and polyclonal spread.2–4,20 In E. cloa-
cae,  CTX-M-15 genes have been described since 2004,21 but
information about the molecular epidemiology of CTX-M-15
producing isolates in this specie is scarce.
Although in South America the CTX-M-2 has been the most
prevalent  type of ESBL detected,9 CTX-M-15 was  reported in
2004  among fecal E. coli isolates from Peru and Bolivia,22 later
Colombia,23 and recently in Argentina.24 In Brazil, the occur-
rence  of CTX-M-15 was  ﬁrst reported in one E. coli clinical
isolate  (in 2006) from a private hospital of São Paulo State,10
and later in K. pneumoniae isolates in a teaching hospital also in
the state of São Paulo with high coefﬁcient of similarity (>86.5)
among  isolates, indicating a close genetic relationship.11 In Rio
de  Janeiro state, the blaCTX-M-15 gene was  found in E. coli iso-
lates  associated both to a dominant clone (ST 410), and ST131
(two  isolates), which is spread worldwide.12
Dice (Opt: 1.50%) (Tol 1.5% - 1.5%) (H > 0.0% S > 0.0%) [0.0% - 100.0%]
PFGE PFGE
70 75 80 85 90 95 100
Fig. 3 – Clinical data and molecular tying of CTX-M-producing E. cloacae.
The presence of KPC has already been described
worldwide,25 including reports from Brazil.16,19,26,27 In
our isolates, the majority of KPC producing isolates carried
also  the blaCTX-M-15 gene. The frequent association of CTX-M
with KPC in K. pneumoniae in this and other studies suggests
the  acquisition of transmissible plasmids carrying blaKPC-2
gene by local endemic strains harboring the blaCTX-M-15 gene.
Among the KPC producing isolates the dominant pulsotype
(pulsotype A) was  found, belonging to ST437, which is dis-
seminated  in ﬁve Brazilian States.19,28,29 This ST437 belonged
to  clonal complex (CC) 11, which is an important complex
because it also includes two STs (ST258 and ST11) that have a
prominent role in the spread of the blaKPC gene. The ST11 has
been  reported in Hungary, Spain and China2,3,30 and has also
been  extensively associated with CTX-M-15 and CTX-M-14.6
The blaKPC gene was not detected in the nine iso-
lates of E. cloacae resistant to ertapenem, perhaps due to
other  possible resistant mechanisms, such as an associa-
tion  between CTX-M production and porin loss that are also
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esponsible for decreased susceptibility to carbapenem, as
reviously  reported.31
Although more  studies need to be conducted to clar-
fy  some questions, this study shows that the increased
requency of CTX-M-15 producing isolates may  have been
nﬂuenced  by both multiple clones and/or several mobile
enetic  elements.
In  conclusion, this study provides additional informa-
ion of the epidemiological scenario of CTX-M-types among
nterobacteriaceae isolates circulating in Brazilian hospitals in
007–2008. This data reinforce the need for continuing surveil-
ance  because this scenario may  have changed over the years.
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